Review paper
ARNI in cardiovascular disease: current evidence and future perspectives
Abstract
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the mainstay of therapy for cardiovascular disease and heart failure (HF). The angiotensin receptor II blocker – neprilysin inhibitor (ARNI), sacubitril-valsartan has an established role in treatment of patients with HF with reduced ejection fraction (HFrEF) based on the results of PARADIGM-HF trial. This trial has provided a strong evidence base for treatment of...
Paper Details
Title
ARNI in cardiovascular disease: current evidence and future perspectives
Published Date
Apr 22, 2020
Journal
Volume
16
Issue
5
Pages
505 - 515